Literature DB >> 29759496

J Waves for Predicting Cardiac Events in Hypertrophic Cardiomyopathy.

Toyonobu Tsuda1, Kenshi Hayashi2, Tetsuo Konno1, Kenji Sakata1, Takashi Fujita1, Akihiko Hodatsu1, Yoji Nagata1, Ryota Teramoto1, Akihiro Nomura1, Yoshihiro Tanaka1, Hiroshi Furusho3, Masayuki Takamura3, Masa-Aki Kawashiri1, Noboru Fujino1, Masakazu Yamagishi1.   

Abstract

OBJECTIVES: This study sought to investigate whether the presence of J waves was associated with cardiac events in patients with hypertrophic cardiomyopathy (HCM).
BACKGROUND: It has been uncertain whether the presence of J waves predicts life-threatening cardiac events in patients with HCM.
METHODS: This study evaluated consecutive 338 patients with HCM (207 men; age 61 ± 17 years of age). A J-wave was defined as J-point elevation >0.1 mV in at least 2 contiguous inferior and/or lateral leads. Cardiac events were defined as sudden cardiac death, ventricular fibrillation or sustained ventricular tachycardia, or appropriate implantable cardiac defibrillator therapy. The study also investigated whether adding the J-wave in a conventional risk model improved a prediction of cardiac events.
RESULTS: J waves were seen in 46 (13.6%) patients at registration. Cardiac events occurred in 31 patients (9.2%) during median follow-up of 4.9 years (interquartile range: 2.6 to 7.1 years). In a Cox proportional hazards model, the presence of J waves was significantly associated with cardiac events (adjusted hazard ratio: 4.01; 95% confidence interval [CI]: 1.78 to 9.05; p = 0.001). Compared with the conventional risk model, the model using J waves in addition to conventional risks better predicted cardiac events (net reclassification improvement, 0.55; 95% CI: 0.20 to 0.90; p = 0.002).
CONCLUSIONS: The presence of J waves was significantly associated with cardiac events in HCM. Adding J waves to conventional cardiac risk factors improved prediction of cardiac events. Further confirmatory studies are needed before considering J-point elevation as a marker of risk for use in making management decisions regarding risk in patients with HCM.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  J waves; hypertrophic cardiomyopathy; ventricular arrhythmias

Mesh:

Year:  2017        PMID: 29759496     DOI: 10.1016/j.jacep.2017.03.010

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  4 in total

1.  Predictive effect of J waves on cardiac compression and clinical prognosis of esophageal tumors: a retrospective study.

Authors:  Songcui Shen; Yichen Xie; Pengliang Ju; Wenzhao Li; Jiayuan Zhang; Ruxin Cai; Ruogu Li
Journal:  J Gastrointest Oncol       Date:  2022-06

Review 2.  Why Is There an Increased Risk for Sudden Cardiac Death in Patients With Early Repolarization Syndrome?

Authors:  Shreyas Yakkali; Sneha Teresa Selvin; Sonu Thomas; Viktoriya Bikeyeva; Ahmed Abdullah; Aleksandra Radivojevic; Anas A Abu Jad; Anvesh Ravanavena; Chetna Ravindra; Emmanuelar O Igweonu-Nwakile; Safina Ali; Salomi Paul; Pousette Hamid
Journal:  Cureus       Date:  2022-07-13

3.  Depolarization versus repolarization abnormality underlying inferolateral J-wave syndromes: New concepts in sudden cardiac death with apparently normal hearts.

Authors:  Michel Haïssaguerre; Koonlawee Nademanee; Mélèze Hocini; Ghassen Cheniti; Josselin Duchateau; Antonio Frontera; Frédéric Sacher; Nicolas Derval; Arnaud Denis; Thomas Pambrun; Rémi Dubois; Pierre Jaïs; David Benoist; Richard D Walton; Akihiko Nogami; Ruben Coronel; Mark Potse; Olivier Bernus
Journal:  Heart Rhythm       Date:  2018-11-02       Impact factor: 6.343

4.  Prognostic Implication of First-Degree Atrioventricular Block in Patients With Hypertrophic Cardiomyopathy.

Authors:  Satoshi Higuchi; Yuichiro Minami; Morio Shoda; Shota Shirotani; Chihiro Saito; Shintaro Haruki; Masayuki Gotou; Daigo Yagishita; Koichiro Ejima; Nobuhisa Hagiwara
Journal:  J Am Heart Assoc       Date:  2020-03-09       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.